Strides Pharma Science announced the acquisition and in-licensing of branded generic products from Sandoz across Sub-Saharan Africa (SSA). This strategic move is expected to position Strides among the top five pharmaceutical players in SSA by sales, more than doubling its regional presence. The transaction, valued at an initial consideration of US$ 12 million, spans key markets like Ghana, Nigeria, and Kenya, and is expected to close by the end of Q2 FY27.
Strides Acquires Sandoz Portfolio in Sub-Saharan Africa
Strides Pharma Science Limited (Strides) today announced that its step-down subsidiary, Strides Pharma International AG (SPIAG), has entered into definitive agreements with Sandoz AG for the acquisition and in-licensing of branded generic products across Sub-Saharan Africa (SSA).
This strategic transaction is designed to significantly enhance Strides’ footprint in the region. The combined business, integrating Strides’ existing operations with the newly acquired Sandoz portfolio, is projected to position Strides as one of the top five pharmaceutical companies in the SSA region by sales, and among the top two in the represented market. The deal more than doubles Strides’ presence in the region.
Scope of the Transaction
The agreement covers four key markets: Western Sahara (10 countries), Ghana, Nigeria, and Kenya. The acquired Sandoz portfolio includes multiple brands across therapeutic segments such as anti-infective, cardiovascular, and dermatology. Several of these individual products generate annual sales exceeding US$ 1 million.
The transaction structure includes products that will be fully acquired by Strides, alongside select products that Strides will continue to market on behalf of Sandoz under a Manufacturing and Supply Agreement to ensure continuity.
Financial Details and Strategic Synergy
The initial consideration for the transaction is set at US$ 12 million, payable at closing and expected to be funded through internal accruals. The transaction is anticipated to be EPS-accretive, driven by profitable branded sales realization and synergy benefits.
Strides anticipates strong strategic synergies, including enhanced market reach, strengthened therapeutic leadership due to Sandoz’s brand equity, and new cross-selling opportunities across an expanded network of doctors and pharmacies. The acquisition unlocks new commercial channels, deepening access to prescribers and healthcare institutions.
Timeline for Completion
The transaction is expected to close by the end of Q2 FY27 (Quarter Ending 30th September 2026), subject to customary closing conditions, including regulatory and antitrust approvals.
Executive Commentary on Africa Strategy
Aditya Kumar, Executive Director, Business Development, emphasized that this acquisition is a significant milestone for Strides’ ‘in Africa for Africa’ strategy. He noted that Africa is one of the fastest-growing geographies for the company, and this deal aligns with the long-term strategy where Ex-US markets are expected to mirror the scale of the US business within a couple of years.
Source: BSE
